Amgen 20150125 & 20160354

Studies are conducted to investigate the efficacy of erenumab in preventing migraine in children and adolescents age 6-18 years that have been diagnosed with chronic (>15 headache days per month) or episodic (>15 headache days per month) migraine headaches. These studies also seek to determine whether erenumab is safe and well tolerated, and whether it causes any side effects in these patients.

The studies consists of a 24-week randomized, double-blind, placebo-controlled phase followed by a 40-week optional dose-level-blinded extension (during which all patients will receive erenumab). Total participation is up to 83 weeks, and includes approximately 10 in-person clinic visits that will take 2-3 hours each.

Contact Person

Irys Caristo, CCRC


Amgen Inc.